Amgen Stock News

Amgen Inc. (NASDAQ:AMGN ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 9:15 AM ET Company Participants Bob Bradway - Chairman and Chief Executive Officer Conference Call Participants Terence Flynn - Morgan Stanley Operator Terence Flynn Great. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclo...

Amgen will test its obesity drug candidate in patients at risk of obesity-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said at a Morgan Stanley healthcare conference on Wednesday.

From obesity to cancer, investors will do well to watch these 6 clinical trials.

THOUSAND OAKS, Calif. , Aug. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m.

THOUSAND OAKS, Calif. , Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m.

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Amgen's stock is fairly valued at 16.6x next year's earnings, supported by robust existing revenue growth and a diversified portfolio. The company's new products, such as Blincyto, Tezspire, and Tepezza, are driving significant revenue growth, validating recent share price appreciation. MariTide, AMGN's GLP-1 candidate, offers potential upside due to its long-lasting effects and less frequent d...

On August 6, Amgen released financial results for the second quarter of 2024, which pleasantly shocked me thanks to strong sales of its oncology and rheumatology franchises. So, Evenity sales reached $391 million for the three months ended June 30, 2024, increasing by 39.1% year-on-year. While sales of an equally important medication, namely Krystexxa, amounted to $294 million in the second qua...